B of A Securities Maintains Buy on Janux Therapeutics, Raises Price Target to $48
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Geoff Meacham has maintained a Buy rating on Janux Therapeutics (NASDAQ:JANX) and doubled the price target from $24 to $48.
March 13, 2024 | 2:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
B of A Securities has maintained a Buy rating on Janux Therapeutics and raised the price target from $24 to $48.
The doubling of the price target by a reputable analyst like Geoff Meacham signals strong confidence in Janux Therapeutics' future performance. This significant increase is likely to positively influence investor sentiment and potentially drive up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100